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Abstract
Background Previous studies regarding the comparative
costs of laparoscopic and open surgery for rectal cancer
provide ambiguous conclusions, and there are no large
randomized trials or long-term follow-up.
Methods A prospective cost-minimization analysis was
carried out by using data of clinical resource use from the
randomized controlled trial COLOR II. Some data needed
for the health economic evaluation were not collected in
the clinical trial; therefore, a retrospective data collection
was made for COLOR II-patients operated at the largest
participating Swedish hospital (n = 105). Sick leave
information was provided by the Swedish social insurance
agency. Unit costs were collected from Swedish sources.
The primary outcome was the difference in mean cost
between laparoscopic and open surgery.
Results The COLOR II-trial enrolled 1044 rectal cancer
patients randomized between laparoscopic and open sur-
gery 2:1. At the 3-year follow-up data for the clinical
variables used in the analysis were available for 74–89 %
of patients. Laparoscopic surgery costs the health care
sector more than the open technique, both at 28 days
($1910, 95 % CI 677–3143) and 3 years ($3854, 95 % CI
1527–6182) after surgery. There were, however, no dif-
ferences in long-term costs to society between laparoscopic
and open surgery ($684, 95 % CI -5799 to 7166).
Conclusions Though the study found short- and long-term
cost differences for the healthcare sector, there was no
difference in regard to the long-term societal perspective.
Future research is suggested to investigate the effects of
sick leave costs using material from a greater number of
patients.
Keywords Health economics  Cost-minimization
analysis  Costs  Rectal cancer surgery
Background
Several smaller series and one large randomized trial, the
COLOR (COlorectal cancer Laparoscopic or Open
Resection) II-trial [1], have shown that laparoscopic sur-
gery for rectal cancer has short-term benefits and is safe in
comparison to open surgery. The short-term outcomes of
the COLOR II-trial found that the laparoscopic group had
less blood loss and a shorter hospital stay, but longer
operating room time [2]. The analysis of the primary
endpoint showed no difference with regard to loco-regional
recurrence rates. There was no statistically significant dif-
ference in 3-year survival between the surgical procedures
[3]. The study continues to monitor the disease-free and
overall survival rates 5 years after surgery. The short-term
outcomes of the ACOSOG Z6051 [4] and ALaCaRT [5]
randomized clinical trials of laparoscopic and open rectal
cancer resections failed to establish non-inferiority in terms
of the pathological and adequate surgical resection out-
comes. These trials have, however, used other endpoints,
both are short-term and the group sizes are such that
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clinically relevant long-term oncological results cannot be
ascertained.
Uncertainties remain regarding the relative costs of
laparoscopic and open rectal cancer surgery. Several
studies performed alongside randomized trials comparing
the costs of laparoscopic and open surgery for rectal cancer
have had short time perspectives [6–9] or have not included
the cost of sick leave [8–10]; the results are difficult to
interpret from a societal viewpoint.
The aim of the present study was to evaluate the cost of
laparoscopic versus open resection for rectal cancer from
both the healthcare and the societal perspective, based on
the randomized COLOR II-trial. The health economic
method employed was a cost-minimization analysis (see
health economic methodology). The costs were assessed at
28 days (short-term analysis) and 3 years (long-term
analysis). The hypothesis was that laparoscopic surgery
would be more costly when assessed at 28 days after the
primary operation but not at 3 years.
Materials and methods
The COLOR II-trial
The COLOR II-trial provided the clinical data for the
present cost study [11]. The study was designed as a non-
inferiority trial undertaken at thirty hospitals in eight
countries (Belgium, Canada, Denmark, Germany, the
Netherlands, Spain, Sweden and South Korea) between
January 2004 and May 2010 [11]. The patients were ran-
domized on a 2:1 basis, 699 patients in the laparoscopic
resection group and 345 in the open resection group. The
trial was stratified by center, location of tumor and radio-
therapy prior to surgery [2, 11]. During the course of the
trial, clinical record forms (CRF) were administered, one
each for the pre-, intra- and postoperative stages (up to
28 days after the operation) and one CRF per year up to
5 years after the index surgery. In case of complications,
reoperations or recurrences an additional CRF was com-
pleted. At the primary endpoint data were available for 771
patients (74 %) regarding loco-regional recurrence and for
903 patients (87 %) concerning overall survival [3]. The
institutional review board at each participating center
approved the trial. All patients provided informed consent
in writing.
Health economic methodology
Health economic evaluations such as cost-effectiveness
analysis are based on the incremental cost for an incre-
mental unit of a clinically relevant outcome (mortality or
morbidity) or a QALY (quality-adjusted life-years) as a
measure of treatment or program effectiveness [12]. Sur-
vival and health-related quality of life [13, 14] were not
statistically different in COLOR II (N.B. non-inferiority
trial), and consequently a cost-minimization rather than a
cost-effectiveness analysis was appropriate for the analysis
[15]. This method implies a comparison of the costs for
treatment alternatives that achieve a common outcome to
an equal degree [12]. The rationale for the included cost
components in the present study is outlined in more detail
in Bjo¨rholt et al. [16]
The cost analysis comprises the health care and the
societal perspective, where the latter adds the cost of sick
leave to the direct healthcare cost. The study period was set
from inclusion into the clinical trial up to 3 years postop-
eratively, including the short- and long-term clinical end-
points of the COLOR II-study. Censoring and missing data
can cause bias in economic studies conducted alongside
clinical trials [17]. In this trial, the return rate of clinical
record forms was high and it was assumed from a clinical
perspective that censored patients and patients with miss-
ing data would not differ from non-censored patients and
patients with complete data in the aspects affecting cost.
One-way sensitivity analysis was employed to challenge
the impact of variables sensitive to censoring mechanisms
and missing data, i.e., reoperation, stoma care and sick
leave. The analysis shows how the difference in mean cost
between the surgical techniques is affected by changes
(±30 %) in cost per variable for each procedure.
Data collection
Resource use
Data on resource use were collected prospectively through
CRF’s in the COLOR II-trial. Details of the use of
resources that were needed for this study, but had not been
collected within the trial (basic laparoscopic equipment,
surgical instruments, anesthesia time and time in recovery
room), were determined using other sources.
The basic equipment required for laparoscopic surgery,
as well as the type and quantity of instruments required for
laparoscopic and open surgery, was determined by con-
clusions drawn from the health economic evaluation of
laparoscopic versus open colon cancer resection within the
framework of the randomized trial COLOR [18] and in
collaboration with senior surgeons. Data regarding duration
of anesthesia and time in the recovery room were collected
from the records of COLOR II-patients operated on at the
Sahlgrenska University Hospital in Sweden (n = 105). The
factor between time in anesthesia and skin-to-skin time was
established for the Sahlgrenska patients and applied on all
COLOR II-patients. The average time in the recovery room
for COLOR II-patients operated on at Sahlgrenska
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University Hospital was extrapolated to all study
participants.
Sick leave was retrieved from the Swedish Social
Insurance Agency for Swedish COLOR II-patients, and the
observed average number of days on sick leave per surgical
technique was calculated. To be able to analyze the total
cost at the patient level, the average number of sick leave
days per surgical technique observed in the Swedish cohort
was applied to the non-Swedish COLOR II-population
using random selection. It was ascertained that the pro-
portion of patients on sick leave in the Swedish cohort, and
the non-Swedish COLOR II-populations was the same.
Unit costs
Unit costs for basic equipment and surgical instruments
were obtained from regional procurement records in
Region Va¨stra Go¨taland, Sweden. The cost per minute in
the operating room, time in anesthesia and time in the
recovery room were derived from the health economic
evaluation of laparoscopic versus open surgery in the
COLOR trial [18]. The unit costs for consumables related
to stoma care were obtained from pharmacy retail prices in
Sweden. The Swedish cost per patient database contains
cost data for approximately 70 % of inpatient care in
Sweden. The unit cost per type of reoperation in this study
was estimated by taking the average cost for the matching
procedure in the cost per patient database. Therefore, the
cost per reoperation was based on a larger sample which
reduced the potential variability in resource use of these
rare and costly events. It was assumed that the type of
reoperation was unrelated to the original surgical tech-
nique, as no significant differences in complications or re-
operations were found in the COLOR II-study [2].
The cost of sick leave was calculated by using the
average monthly wage (provided by Statistics Sweden)
with addition of the social security and supplementary
pension fees. All prices were inflation adjusted for 2013
SEK using the consumer price index provided by Statistics
Sweden. Costs were converted from SEK to the average
value of the US dollar in 2013 ($1 = 6.51 SEK).
Statistical methods
The distribution of cost data is non-negative and right
skewed due to the low number of patients incurring par-
ticularly high costs, a common phenomenon in studies
involving resource items with high unit costs such as
hospital care, reoperations and sick leave. The average cost
will consequently be higher than the cost of the average
patient, but it is still meaningful as it enables the calcula-
tion of the total cost of treating all patients with the new
therapy [17]. Due, however, to the central limit theorem
statistical inference based on the normality assumption
regarding average cost is valid despite the skewed distri-
bution. A non-parametric bootstrap was included as a
robustness check of the results [19].
Results
For the health economic study, 699 patients in the
laparoscopic group and 345 in the open group were
available for analysis (Fig. 1). Information relevant for the
short-term outcomes of the study was available for between
98 and 100 % of the patients. Concerning the long-term
analysis data were available for 74–89 % of the patients.
The baseline clinical characteristics (Table 1) were not
significantly different between laparoscopic and open
resection. The resource use and the corresponding unit
costs associated with each treatment are shown in Tables 2
and 3, respectively. Table 4 displays the mean cost per
resource use category and treatment, and Table 5 shows the
difference in means and the main outcome of the study.
The bootstrap method did not affect the p value for any of
the results in Table 5, but the confidence intervals became
narrower.
Healthcare perspective
The mean healthcare cost per patient (Table 5) during the
28 days following surgery was significantly higher in the
laparoscopic group $16226 (SEK, 105694) than in the open
group $14316 (SEK, 93253), yielding a difference of
$1910 (SEK, 12440) (CI95 % 677–3143). Three years after
surgery, this difference had increased to $3854 (SEK
25107) (CI95 % 1527–6182).
Societal perspective
From the societal perspective, the mean cost per patient
(Table 5) at 28 days following surgery was significantly
higher in the laparoscopic group $18113 (SEK, 117990) than
in the open group $16261 (SEK 105926), with a difference of
$1852 (SEK, 12063) (95 % CI 533–3171). Three years after
surgery, the difference was not significant and had decreased
to $684 (SEK, 4453) (95 % CI -5799 to 7166).
Sensitivity analyses
Sensitivity analyses can be found in Table 6. From the
short-term healthcare and societal perspectives length of
hospital stay were the only variable demonstrating signif-
icant sensitivity (difference in mean cost became negative)
to the variation of the base case value. Long-term societal
costs were affected by the number of days on sick leave.
Surg Endosc (2017) 31:1225–1234 1227
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Additional sensitivity analysis
The incidence of colostomy had considerable impact on the
study result and so did the number of days on sick leave. A
detailed analysis of the data showed that patients in the
open surgery group were older, and therefore, fewer were
eligible for sick leave compared with patients in the
laparoscopic group. Numerically more patients on sick
leave in the laparoscopic group died earlier compared to
the open group which resulted in a lower cost of sick leave
in the laparoscopic group. As survival did not significantly
differ between the groups, this was most likely a random
Fig. 1 Study flow chart and
COLOR II
Table 1 Baseline clinical
characteristics and pathology
Characteristics Laparoscopic surgery (n = 699) Open surgery (n = 345)
Gender, no. (%)
Male 448/699 (64) 211/345 (61)
Female 251/699 (36) 134/345 (39)
Age, mean (SD), years 66.8 (10.5) 65.8 (10.9)
American Society of Anesthesiologists classification, no. (%)
I 156/678 (23) 65/338 (19)
II 386/678 (57) 211/338 (62)
III 131/678 (19) 61/338 (18)
IV 5/678 (\1) 1/338 (\1)
Missing data 21/699 (3) 7/345 (2)
Body-mass index, mean (SD), kg/m2 26.1 (4.5) 26.5 (4.7)
Location of tumor (distance from anal verge), no. (%)
Upper rectum (10–15 cm) 223/699 (32 %) 116/345 (34)
Middle rectum (5–10 cm) 273/699 (39 %) 136/345 (39)
Lower rectum (\5 cm) 203/699 (29 %) 93/345 (27)
Clinical stage, no. (%)
I 201/667 (30) 96/329 (29)
II 209/667 (31) 107/329 (33)
III 257/667 (38) 126/329 (38)
Missing data 32/699 (5) 16/345 (5)
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finding due to sick leave only having been examined in a
small sub-group of the COLOR II-trial. The mean number
of days with a colostomy was higher in the laparoscopic
group, partly due to numerically more laparoscopic patients
subject to abdominoperineal resection at the index opera-
tion and partly due to longer survival time in the sub-group
of colostomy patients in the laparoscopic group. Additional
sensitivity analyses were, therefore, performed and the
results showed that excluding the costs of stoma material
the difference in mean cost per patient to the health care
sector ($1886, 95 % CI 657–3115) (SEK, 12286) was
similar to the base case analysis at 28 days after the index
Table 2 Clinical resource use





Basic laparoscopic equipment, no (%) 699 (100) 0 (0) COLOR II
Surgical instruments, no (%)a COLOR II
TME 396/699 (57) 219/345 (63)
Other (APR, PME) 294/699 (42) 126/345 (37)
Missing 9/699 (1) 0/345 (0)
Skin-to-skin time, min 247 (83) 200 (69) COLOR II
Time in anesthesia, minb 306 (104) 256 (89) Subset of COLOR II-patients
Time in recovery room, minb,c 992 (N/A) 1054 (N/A) Subset of COLOR II- patients
Length of hospital stay\ 28 days, days 11.5 (6.5) 12.1 (6.0) COLOR II
Length of hospital stay\ 3 years, days 12.8 (11.5) 13.4 (11.0) COLOR II
Days with ileostomy\ 28 days, days 10.5 (13.5) 10.8 (13.6) COLOR II
Days with ileostomy\ 3 years, days 91 (182) 80 (139) COLOR II
Days with colostomy\ 28 days, days 9.7 (13.2) 8.1 (12.6) COLOR II
Days with colostomy\ 3 years, days 363 (502) 281 (461) COLOR II
No. (%) of patients with reoperation\ 28 days COLOR II
No 588/697 (84) 299/345 (87)
Yes 109/697 (16) 46/345 (13)
No. (%) of patients with reoperation\ 3 years COLOR II
No 459/697 (66) 240/345 (70)
Yes 238/697 (34) 105/345 (30)
Reasons for reoperation (\ 3 years)d COLOR II
Recurrence 28 14
Complication 217 89
Stoma reversal 68 28
Complication and new stoma 48 21
Not related to rectal surgery 10 7
Sick leave\ 28 days, dayse 6.2 (11.6) 6.4 (11.8) Swedish Social Insurance
Agency
Sick leave\ 3 years, dayse 75 (137) 86 (157) Swedish Social Insurance
Agency
Values are mean (standard deviation) unless stated otherwise
a TME-Resection with total mesorectal excision, APR-Abdominoperineal resection, PME-Resection with partial mesorectal excision. Described
in more detail in van der Pas et al. [2]. A set of surgical instruments used for open and laparoscopic TME and non-TME was determined in
collaboration with senior surgeons. The number of TME and non-TME was collected from the COLOR II-trial
b Collected within the Swedish cohort of COLOR II operated at the Sahlgrenska University Hospital, Gothenburg
c The mean value of time in recovery room in the Swedish cohort and in the global study population all patients were assigned these mean
values, i.e., std. dev. not possible to calculate
d Long-term data (\ 3 years) from RCT COLOR II previously not published. Several patients have had more than one reoperation collected
within the Swedish cohort of COLOR II only
e Collected within the Swedish cohort of COLOR II only
Surg Endosc (2017) 31:1225–1234 1229
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Table 3 Unit costs
Resource use category Unit cost (USD) Unit Source
Basic laparoscopic equipment 281 Per laparoscopic resection Region Va¨stra Go¨taland, Sweden
Surgical instrumentsa Region Va¨stra Go¨taland, Sweden
Open TME 931 Per open TME
Laparoscopic TME 2101 Per laparoscopic TME
Open non-TME 784 Per open non-TME
Laparoscopic non-TME 1779 Per laparoscopic non-TME
Skin-to-skin time 11 Per minute Janson et al. 2004
Duration of anesthesia 5 Per minute Janson et al. 2004
Time in recovery room 1 Per minute Janson et al. 2004
Length of hospital stay 531 Per day Janson et al. 2004
Ileostomy 12 Per day Pharmacy sales price
Colostomy 18 Per day Pharmacy sales price
Reoperationb N/A Per type of reoperation Swedish association of local authorities and regions
Sick leave 303 Per day Statistics Sweden
a TME-Resection with total mesorectal excision, APR-Abdominoperineal resection and PME-Resection with partial mesorectal excision.
Described in more detail in van der Pas et al. [2]
b The type of reoperation was collected within the COLOR II-trial. The unit cost per type of reoperation was collected from a national database
(Swedish association of local authorities and regions) containing the costs for approximately 70 % of the Swedish in-patient episodes of care
Table 4 Mean cost and difference in mean cost per resource use category
Resource use category Mean cost per patient/laparoscopic surgery
(USD)
Mean cost per patient/open surgery
(USD)




281 (0) N/A 281 (N/A)
Surgical instruments 1964 (159) 878 (71) 1087 (7)
Skin-to-skin time 2676 (898) 2161 (750) 514 (53)
Duration of anesthesia 1545 (526) 1293 (451) 252 (32)
Time in recovery room 1074 (N/A) 1141 (N/A) -67 (N/A)
Length of hospital stay
28 days 6129 (3427) 6431 (3210) -302 (221)
3 years 6796 (6129) 7117 (5844) -321 (398)
Stoma
Ileostomy 28 days 124 (158) 127 (160) -3,6 (10)
Ileostomy 3 years 1070 (2142) 941 (1630) 129 (120)
Colostomy 28 days 174 (238) 146 (227) 27 (15)
Colostomy 3 years 6519 (9022) 5038 (8288) 1481 (578)
Reoperation
28 days 2397 (7280) 2199 (7591) 198 (486)
3 years 5902 (11,867) 5323 (11,580) 578 (775)
Sick leave
28 days 1888 (3447) 1945 (3575) -58 (230)
3 years 22,793 (41,618) 25,964 (47,712) -3171 (3014)
Values are mean (standard deviation), except difference in mean costs (standard error)
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surgery. At 3 years the difference in mean health care cost
per patient ($2245, 95 % CI 270–4219) (SEK, 14621) was
lower compared to the base case analysis ($3854).
Laparoscopic surgery was numerically less costly per
patient for society than open surgery -$926 (SEK, -6034)
(95 % CI -7261 to 5409) at 3 years after primary opera-
tion. In the short time perspective, it made little difference
($1828, 95 % CI 513–3144) (SEK, 11909).
Discussion
This health economic evaluation of laparoscopic and open
surgery for rectal cancer in the framework of the ran-
domized trial COLOR II showed that laparoscopy was
significantly more costly from the societal perspective at
28 days, but no statistical significance was detected at
3 years. From a healthcare perspective, laparoscopy was
more costly than open surgery at both 28 days and 3 years.
The one-way sensitivity analyses showed that variations
in sick leave and the incidence and days with colostomy
had a large impact on the results. Data on sick leave were
elicited for the Swedish sub-group only (n = 251), which
increased the risk of random findings. This is a common
problem for costly resource use items that may vary
without relation to the studied interventions. In this study,
the finding was a disadvantage to the results in the open
surgery group. On the other hand, patients with a cancer in
the lowest part of the rectum, who received a colostomy
due to abdominoperineal resection, lived longer (n.s.) and
were numerically more frequent in the laparoscopic group
[3]. Since colostomies are costly and a longer follow-up
time involves further costs, this was a disadvantage for the
laparoscopic group. The additional sensitivity analyses
confirmed that when stoma costs were deducted from the
health care costs, the difference in mean cost per patient
was reduced. For the long-term societal costs, the differ-
ence (laparoscopic minus open surgery) in mean cost per
patient changed from $684 (base case) to -$926 (n.s.).
There are few findings about the cost of rectal cancer
surgery and they are divergent. Franks et al. [6] reported on
a randomized trial including the initial 3 months after
index surgery and found no significant difference in soci-
etal costs between open and laparoscopic surgery, but the
time chosen for their analysis differs from that of our
analysis and the number of patients were fewer in their
study. Son et al. [8] found statistically significant higher
median costs for laparoscopic rectal resection compared to
open, utilizing data for a cohort of a randomized trial.
Using median costs makes it difficult to compare it to the
results of the present study, since our results present mean
costs. Their health economic evaluation covered the first
three postoperative months and healthcare costs only,
whereas our analysis covers 3 years and includes societal
costs.
The results from the societal perspective in this trial
correspond to those from the earlier trial of laparoscopic
versus open surgery for colon cancer (COLOR) [18],
Table 5 Mean total cost and difference in mean total cost per surgical technique
Perspective and time of
analysis
Mean total cost laparoscopic
resection (USD)
Mean total cost open resection
(USD)
Difference in mean total cost
(95 % CI)
p value
Health care costs 28 days
Parametric 16,226 (10,140) 14,316 (10,361) 1910 (677 to 3143) \0.002
Nonparametric
(bootstrap)
1910 (685 to 3123) \0.003
Health care costs 3 years
Parametric 27,686 (46,198) 23,831 (51,993) 3854 (1527 to 6182) \0.001
Nonparametric
(bootstrap)
3854 (1491 to 6053) \0.001
Societal costs 28 days
Parametric 18,113 (9524) 16,261 (9591) 1852 (533 to 3171) \0.006
Nonparametric
(bootstrap)
1852 (391 to 3110) \0.006
Societal costs 3 years
Parametric 50,479 (18,162) 49,795 (17,719) 684 (-5799 to 7166) 0.84
Nonparametric
(bootstrap)
684 (-5698 to 7255) 0.84
Values are mean (standard deviation) unless stated otherwise. Bootstrap confidence intervals and p values are based on 2000 replications
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Table 6 Sensitivity analyses
Perspective and time of analysis Variable Change in cost Difference in mean (USD) 95 % CI
Health care costs 28 days
Base case cost N/A 1910 677 3143
Skin-to-skin time Lap -30 % 1103 -125 2330
Lap ?30 % 2671 1430 3912
Open -30 % 2524 1293 3755
Open ?30 % 1250 13 2487
Length of hospital stay Lap -30 % 79 -1097 1255
Lap ?30 % 3740 2444 5037
Open -30 % 3839 2632 5046
Open ?30 % -19 -1282 1243
Colostomy Lap -30 % 5970 2671 9269
Lap ?30 % 1700 -1708 5108
Open -30 % 1853 -641 4348
Open ?30 % 1927 -568 4422
Reoperation Lap -30 % 1191 31 2350
Lap ?30 % 2629 1299 3958
Open -30 % 2570 1505 3634
Open ?30 % 1250 -180 2679
Health care costs 3 years
Base case cost N/A 3854 1527 6182
Length of hospital stay Lap -30 % 1824 -413 4061
Lap ?30 % 5884 3455 8314
Open -30 % 5989 3706 8272
Open ?30 % 1719 -658 4097
Reoperation Lap -30 % 2084 -115 4283
Lap ?30 % 5625 3181 8068
Open -30 % 5451 3365 7538
Open ?30 % 2257 -308 4823
Societal costs 28 days
Base case cost N/A 1852 533 3171
Surgical instruments Lap -30 % 1269 -50 2588
Lap ?30 % 2435 1115 3755
Open -30 % 2115 796 3434
Open ?30 % 1589 269 2908
Skin-to-skin time Lap -30 % 1124 -102 2351
Lap ?30 % 2695 1455 3935
Open -30 % 2547 1316 3777
Open ?30 % 1273 37 2509
Length of hospital stay Lap -30 % 21 -1244 1286
Lap ?30 % 3683 2302 5063
Open -30 % 3781 2486 5076
Open ?30 % -77 -1424 1270
Reoperation Lap -30 % 1133 -126 2391
Lap ?30 % 2571 1155 3987
Open -30 % 2512 1344 3679
Open ?30 % 1192 -321 2705
Sick leave Lap -30 % 1286 -7 2579
Lap ?30 % 2418 1064 3772
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although the time frame was shorter in that study. Three
previous studies have reported the cost of sick leave after
colorectal cancer. In Franks et al. [6], the average cost of
sick leave after rectal cancer surgery was higher in the
laparoscopic than in the open resection group (the differ-
ence in average cost was £103 95 % CI £-576 to £368).
King et al. [7] reported the difference in average cost of
productivity loss between laparoscopic and open resection
of colorectal cancer within an enhanced recovery program
to be £274 (bootstrap CI at 2.5 and 97.5 %, -386 to 983.2)
less in the laparoscopic resection group. In a recent study
by Crawshaw et al. [20], the difference in sick leave after
colectomy was estimated to be on average 2.78 (95 % CI
1.93–3.59) days longer in the open resection group than in
the laparoscopic resection group. That study was retro-
spective and based on national health insurance claims in
USA. They evaluated health care utilization up to 1 year
after primary operation and found the mean cost to be
lower following laparoscopic surgery. Our study has a
longer time perspective (3 years) and is based on a ran-
domized controlled trial.
In the present study, the length of hospital stay was
considerable in both groups, although 1 day shorter (me-
dian) in the laparoscopic group. The trial protocol pre-
scribed that the same local principles for discharge should
be applied for both groups and did not include the
enhanced recovery after surgery (ERAS) concept [21]. The
difference in hospital stay, however, between laparoscopic
and open colorectal surgery is consistent with studies
including enhanced recovery programs [22, 23]. The sen-
sitivity analyses conducted in the present study indicated a
potential for cost saving if length of hospital stay can be
shortened. In one study, King et al. [7] evaluated the costs
following laparoscopic and open surgery after colorectal
cancer surgery within an enhanced recovery program and
found a difference in mean cost of £354 (95 % CI -2 167
to 2 992) favoring laparoscopic surgery.
The strengths of our study include that it is based on
clinical results from a large randomized trial with a mul-
ticenter design and that the principles for the health eco-
nomic analysis were outlined before the start of the
randomized trial. Thus, the clinical record forms included
variables of importance for the economic analysis. The
study also had a high rate of returned clinical record forms.
A limitation is that the present health economic analysis
was a secondary objective within the randomized trial
COLOR II and the sample size, thus, not calculated for the
health economic outcomes. Further, some of the resource
units are for a sub-group of patients of the COLOR II-trial,
which adds to the uncertainty of these variables.
In conclusion, laparoscopic surgery for rectal cancer is
more costly than open surgery from the health care per-
spective. It is important, however, that the cost of sick
leave is taken into account to ensure inclusion of all costs
arising as a consequence of the surgical method chosen. In
the present study, sick leave was investigated in the
Swedish cohort only which was too small to detect a true
difference between the treatments. Future research is sug-
gested to investigate the sick leave costs of rectal cancer
surgery.
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Table 6 continued
Perspective and time of analysis Variable Change in cost Difference in mean (USD) 95 % CI
Open -30 % 2436 1132 3740
Open ?30 % 1268 -71 2607
Societal costs 3 years
Base case cost N/A 684 -5799 7166
Skin-to-skin time Lap -30 % 3069 749 5389
Lap ?30 % 4640 2305 6974
Open -30 % 4491 2189 6794
Open ?30 % 3217 887 5548
Sick leave Lap -30 % -6154 -12,241 -67
Lap ?30 % 7522 541 14,502
Open -30 % 8473 3121 13,825
Open ?30 % -7106 -14,852 641
Lap Laparoscopic resection, open open resection
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